Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Integrin ß1 polymorphisms and bleeding risk after coronary artery stenting.

Thienel M, Lüsebrink E, Kastrati A, Dannenberg L, Polzin A, Schulz C, Massberg S, Petzold T.

Mol Biol Rep. 2019 Jul 29. doi: 10.1007/s11033-019-05003-2. [Epub ahead of print]

PMID:
31359383
2.

Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention.

Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, Richardt G, Schulz S, Laugwitz KL, Massberg S, Schömig A, Kastrati A.

Circulation. 2012 Mar 20;125(11):1424-31. doi: 10.1161/CIRCULATIONAHA.111.060871. Epub 2012 Feb 17.

PMID:
22344040
3.
4.

Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.

Vranckx P, Leonardi S, Tebaldi M, Biscaglia S, Parrinello G, Rao SV, Mehran R, Valgimigli M.

Eur Heart J. 2014 Oct 1;35(37):2524-9. doi: 10.1093/eurheartj/ehu161. Epub 2014 Apr 21.

PMID:
24755007
6.

Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study.

Kwon TJ, Tantry US, Park Y, Choi YM, Ahn JH, Kim KH, Koh JS, Park JR, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Smith SC Jr, Jeong YH.

Thromb Haemost. 2016 May 2;115(5):979-92. doi: 10.1160/TH15-05-0366. Epub 2016 Jan 21.

PMID:
26790469
7.

A prospective randomised comparison of minor bleedings in transradial vs. transfemoral access percutaneous coronary interventions for STEMI: a new FEMORAL bleeding classification.

Kołtowski L, Filipiak KJ, Tomaniak M, Kochman J, Pietrasik A, Rdzanek A, Huczek Z, Scibisz A, Mazurek T, Opolski G.

Kardiol Pol. 2014;72(9):790-7. doi: 10.5603/KP.a2014.0109. Epub 2014 May 20.

8.
9.

Impact of in-hospital bleeding according to the Bleeding Academic Research Consortium classification on the long-term adverse outcomes in patients undergoing percutaneous coronary intervention.

Yoon YH, Kim YH, Kim SO, Lee JY, Park DW, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2015 Jan 1;85(1):63-71. doi: 10.1002/ccd.25308. Epub 2014 Jul 30.

PMID:
24282105
10.

Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.

Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW.

JACC Cardiovasc Interv. 2011 Feb;4(2):191-7. doi: 10.1016/j.jcin.2010.10.011.

11.

Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.

Porto I, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, Ten Berg J, Widimský P, Le Gall N, Zagar AJ, LeNarz LA, Miller D, Montalescot G; ACCOAST Investigators.

JACC Cardiovasc Interv. 2016 May 9;9(9):897-907. doi: 10.1016/j.jcin.2016.01.041.

12.

Number of severe bleeding complications according to classification used: Is unified classification of bleeding complications really necessary?

Sionova M, Blasko P, Jirous S, Vindis D, Rokyta R, Posch L, Motovska Z.

Cardiol J. 2015;22(6):665-74. doi: 10.5603/CJ.a2015.0044. Epub 2015 Jul 23.

PMID:
26202655
13.

Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.

Barthélémy O, Silvain J, Brieger D, Mercadier A, Lancar R, Bellemain-Appaix A, Beygui F, Collet JP, Costagliola D, Montalescot G.

Catheter Cardiovasc Interv. 2012 Jan 1;79(1):104-12. doi: 10.1002/ccd.23164. Epub 2011 Dec 8.

PMID:
22162411
14.

Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trial.

Motovska Z, Kvasnicka J, Hajkova J, Kala P, Simek S, Bobcikova P, Petr R, Bilkova D, Poloczek M, Miklik R, Fischerova M, Maly M, Widimsky P.

Atherosclerosis. 2010 Oct;212(2):548-52. doi: 10.1016/j.atherosclerosis.2010.07.006. Epub 2010 Jul 16.

PMID:
20691446
15.

Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention.

Zhang JH, Wang J, Tang XF, Yao Y, Zhang Y, Ma YL, Xu B, Gao RL, Song L, Gao Z, Chen J, Wu Y, Yang YJ, Meng XM, Yuan JQ.

Platelets. 2016;27(1):75-9. doi: 10.3109/09537104.2015.1034096. Epub 2015 Apr 22.

PMID:
25901734
16.

Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes.

De Carlo M, Borelli G, Gistri R, Ciabatti N, Mazzoni A, Arena M, Petronio AS.

Catheter Cardiovasc Interv. 2009 Sep 1;74(3):408-15. doi: 10.1002/ccd.22008.

PMID:
19360863
17.

Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention.

Matic DM, Milasinovic DG, Asanin MR, Mrdovic IB, Marinkovic JM, Kocev NI, Marjanovic MM, Antonijevic NM, Vukcevic VD, Savic LZ, Zivkovic MN, Mehmedbegovic ZH, Dedovic VM, Stankovic GR.

Heart. 2014 Jan;100(2):146-52. doi: 10.1136/heartjnl-2013-304564. Epub 2013 Oct 31.

PMID:
24179161
18.

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.

Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, Moliterno DJ, Wallentin L, Held C, Aylward PE, Cornel JH, Bode C, Huber K, Nicolau JC, Ruzyllo W, Harrington RA, Tricoci P.

J Am Coll Cardiol. 2016 May 10;67(18):2135-2144. doi: 10.1016/j.jacc.2016.02.056.

19.

Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).

Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC.

JACC Cardiovasc Interv. 2013 Aug;6(8):854-63. doi: 10.1016/j.jcin.2013.04.009.

20.

CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.

Wang JY, Zhang YJ, Li H, Hu XL, Li MP, Song PY, Ma QL, Peng LM, Chen XP.

Gene. 2018 Dec 15;678:226-232. doi: 10.1016/j.gene.2018.08.027. Epub 2018 Aug 7.

PMID:
30096456

Supplemental Content

Support Center